English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe NCCN Oncology Research Program (ORP) announces funding of a project that will underpin innovative research on optimal management of side effects secondary to treatment with poly ADP ribose polymerase inhibitors (PARPi).
Tag: nccn oncology research program
NCCN Oncology Research Program Celebrates 25 Years of Advancing Cancer Science
The National Comprehensive Cancer Network (NCCN)’s research arm achieves major milestone, showcasing years of success in fostering innovation and knowledge discovery that improves the lives of patients with cancer.
NCCN Announces Funding for Small Cell Lung Cancer Research Projects
The National Comprehensive Cancer Network’s Oncology Research Program selects projects focused on reducing gaps in patient care for people with limited-stage (LS) and extensive stage (ES) small cell lung cancer.
NCCN Announces Research Funding for Biomarker-Directed Therapy in Metastatic Colorectal Cancer, in Collaboration with Fight CRC and Pfizer
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) today announced new grants awarded to improve quality initiatives focused on optimizing biomarker-directed therapy in metastatic colorectal cancer.
NCCN Announces Funding for Bladder Cancer Research Projects, in Collaboration with Pfizer and EMD Serono
The National Comprehensive Cancer Network’s Oncology Research Program selects projects focused on improving patient care and outcomes in locally advanced or metastatic bladder cancer.
NCCN Foundation Announces Awards for Rising Cancer Research Leaders
National Comprehensive Cancer Network’s Oncology Research Program to oversee projects from early-career investigators advancing key areas for study in cancer care and biology, such as novel combination therapy, equitable access to cellular therapies, immune cell dysfunction, liquid biomarkers, genetic ancestry, oncogenic vulnerabilities, and MAIT cell antitumor activity.
NCCN Announces Funding for Early-Stage Non-Small Cell Lung Cancer Projects, in Collaboration with AstraZeneca
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer in collaboration with AstraZeneca.
NCCN Announces Funding for Prostate Cancer Research Projects, in Collaboration with Pfizer and Astellas
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on the use of enzalutamide in treating people with prostate cancer.
NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology, Inc.
The NCCN Oncology Research Program (ORP) announces projects that have been selected for funding to evaluate neratinib in various tumor types, supported by a grant from Puma Biotechnology, Inc.
NCCN Foundation Announces Awards for Rising Cancer Research Leaders
National Comprehensive Cancer Network announces recipients of 2021 NCCN Foundation Young Investigator Awards; projects from early-career investigators to advance research in cancer prevention, racial disparities in screening, immunotherapy, new insights in radiotherapy, and CAR T-cell therapy.
NCCN Announces New Biosimilars Research Projects in Oncology in Collaboration with Pfizer
National Comprehensive Cancer Network Oncology Research Program selects ten projects to receive funding to study the safe, effective, and efficient adoption of biosimilars in oncology.
Crystal Denlinger Named Chief Scientific Officer for National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) announces Crystal S. Denlinger, MD, FACP, as incoming Senior Vice President, Chief Scientific Officer. Dr. Denlinger will help to steer strategic direction for the nonprofit as well as oversee the NCCN Oncology Research Program (ORP).
NCCN Announces Research Projects Exploring Axitinib in Various Cancers, in Collaboration with Pfizer
National Comprehensive Cancer Network Oncology Research Program announces selected studies on adding axitinib, an oral VEGF inhibitor, to treatment for melanoma, colorectal cancer, and hepatocellular carcinoma (HCC), in collaboration with Pfizer.
Grantees Awarded as Part of the Breast Cancer Research Project Between NCCN and Lilly Oncology
The NCCN Oncology Research Program (ORP) today announced five projects selected to receive funding for clinical and preclinical evaluation of abemaciclib, a cyclin dependent kinase (CDK) 4 & 6 inhibitor used in the treatment of HR+ and HER2- breast cancer.
NCCN Oncology Research Program, with Taiho Oncology, to Explore New Research into Oral Medication Targeting Tumor Suppression Genes
The NCCN Oncology Research Program announced plans to develop a program to scientifically evaluate and facilitate clinical trials on the efficacy of decitabine and cedazuridine with research funding provided by Taiho Oncology.
NCCN Oncology Research Program Announces Projects Selected for Funding to Study Futibatinib in Tumors with Aberrant FGFR Expression, in Collaboration with Taiho Oncology
The NCCN Oncology Research Program (ORP) today announced four projects selected to receive funding for clinical and pre-clinical evaluation of futibatinib (TAS-120) in collaboration with Taiho Oncology.
NCCN Explores Adoption of Biosimilars in Oncology in Collaboration with Pfizer
National Comprehensive Cancer Network issues Request for Proposals (RFP) for projects that develop and validate enduring approaches to improve the safe, effective, and efficient adoption of biosimilars in oncology.
NCCN Foundation Awards Leading Young Investigators Advancing Cancer Research for Adults and Children
NCCN and the NCCN Foundation announce five new recipients for the 10th annual NCCN Foundation Young Investigator Awards (YIA) Program, overseen by the NCCN Oncology Research Program (ORP)
NCCN Announces Projects to Improve Ovarian Cancer Care, with AstraZeneca
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) announces four projects selected to receive support directed towards improving the quality of care for advanced ovarian cancer patients, funded through a collaboration with AstraZeneca.
NCCN and AstraZeneca Announce Projects to Explore Quality Improvements in Lung Cancer
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) today announced three research projects selected to receive funding to improve healthcare provider performance and/or healthcare quality, focusing on enhancing patient care and outcomes for people with NSCLC.
NCCN Oncology Research Program to Oversee Trials of the FGFR Inhibitor Futibatinib in Tumors with Aberrant FGFR Expression, in Collaboration with Taiho Oncology
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) announces plans to evaluate futibatinib (TAS-120), an inhibitor of the fibroblast growth factor receptor (FGFR).
NCCN Announces Projects Funded for Metastatic Breast Cancer Grant Program, in Collaboration with Pfizer
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces proposals selected for funding, in collaboration with Pfizer Global Medical Grants, to improve the quality of care and outcomes for people with metastatic breast cancer (MBC).